News 
Market Data 
Discover
Replies to post #267699 on Avid Bioservices Inc (CDMO)
07/05/16 9:35 AM
Is it still time for Roche to occupy the Bavituximab field now that not only AstraZeneca but also Merck are clearly involved in it and now that the NCCN members are going to run several clinical trials and Memorial Sloan Kettering is working with the drug? What can they achieve? Getting approximately the SAME results as the other PD/CTLA combinations with bavituximab but then much later because the others will again have established SOC before them because they are already on the program. It looks to me that Roche/Genetech has that T-shirt already today in the mono-therapy I-O war where they ended at the best on the 3rd place after BMY/MERCK. It kind of illustrates GILD's CEO statement about BP latency.
Is Roche going to let that happen AGAIN? Probably not, this I-O market will dominate the oncology segment, and possible others, for at least a decade. They cannot effort not to be part of it and miss profits to invest in whatever is next in medical science land. But then why don't we see or hear from them. At the best Roche/Genentech gets mentioned for the use of Bavi-PNG in Digital Imagine and actually not even officially but in some mingling talks at the annual meeting by CEO King and only after being asked a DIRECT and difficult to avoid QUESTION on the matter.
So is it thinkable that Roche talks to PPHM but not about bavituximab. Could they be more interested in trying to break back into the I-O race by skipping bavituximab all together and going for the turbo version, namely BetaBodies? Fresh patents, no competition, no known collaboration so the complete field would be available in one big bite!
Analysis of PtdSer exposure on platelets aggregated at a thrombus in a laser/ROS injury model.
..
..
http://movie-usa.glencoesoftware.com/video/10.1073/pnas.1516594112/video-1A
http://movie-usa.glencoesoftware.com/video/10.1073/pnas.1516594112/video-1B
http://movie-usa.glencoesoftware.com/video/10.1073/pnas.1516594112/video-2A
http://movie-usa.glencoesoftware.com/video/10.1073/pnas.1516594112/video-2B
http://www.pnas.org/content/112/41/12800.full.pdf
Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells
Castaño, E; Dalmau, M.; Barragán, M; Pueyo, G; Bartrons, R; Gil, J. (1999)
Publisher: Nature Publishing Group
Journal: British Journal of Cancer
Languages: English
Types: Article
Subjects: Regular Article, aspirin, apoptosis, caspases, colon cancer, HT-29
Identifiers:doi:10.1038/sj.bjc.6690690, pmc:PMC2362852
The induction of cell death by aspirin was analysed in HT-29 colon carcinoma cells. Aspirin induced two hallmarks of apoptosis: nuclear chromatin condensation and increase in phosphatidylserine externalization. However, aspirin did not induce either oligonucleosomal fragmentation of DNA, decrease in DNA content or nuclear fragmentation. The effect of aspirin on Annexin V binding was inhibited by the caspase inhibitor Z-VAD.fmk, indicating the involvement of caspases in the apoptotic action of aspirin. However, aspirin did not induce proteolysis of PARP, suggesting that aspirin does not increase nuclear caspase 3-like activity in HT-29 cells. This finding may be related with the ‘atypical’ features of aspirin-induced apoptosis in HT-29 cells. © 1999 Cancer Research Campaign
https://www.openaire.eu/search/publication?articleId=od_______908::5a874943206d0fe84e2f9360c0e03731
However, just like with our mayonnaise immuno-therapy needs some GENERIC component to allow these anti-body combinations to be effective at their maximum. What is needed is what is called the conditioning of the tumour environment. It becomes more clear every day that the general MOA of the combo's is to 'light up' the problems in order for the immune system to kick in and take care of it. This can be dome by preventing the problem to be masked and remain invisible from the immune system or by attracting the attention of the immune system to a problem that would otherwise not be anyways visible.
...
...
We all know that this game, actually real war although some on here may not experience it that way, is all about getting approved and becoming SOC so that insurance and social security include the drug in their pay-back programs. And to become SOC you must beat the previous SOC.
Is it still time for Roche to occupy the Bavituximab field now that not only AstraZeneca but also Merck are clearly involved in it and now that the NCCN members are going to run several clinical trials and Memorial Sloan Kettering is working with the drug? What can they achieve? Getting approximately the SAME results as the other PD/CTLA combinations with bavituximab but then much later because the others will again have established SOC before them because they are already on the program. It looks to me that Roche/Genetech has that T-shirt already today in the mono-therapy I-O war where they ended at the best on the 3rd place after BMY/MERCK. It kind of illustrates GILD's CEO statement about BP latency.
Is Roche going to let that happen AGAIN? Probably not, this I-O market will dominate the oncology segment, and possible others, for at least a decade.
...
...
BetaBodies jumping Bavituximab!
...
...
08/28/20 11:41 PM
